Posted by Michael Wonder on 14 Oct 2025
Akamis Bio receives FDA fast track designation for NG-350A for the treatment of mismatch repair proficient locally advanced rectal cancer
14 October 2025 - NG-350A is a systemically delivered oncolytic immunotherapy driving intra-tumoral expression of a CD40 agonist monoclonal antibody.
Akamis Bio today announced that the US FDA has granted fast track designation to NG-350A for the treatment of mismatch repair-proficient locally advanced rectal cancer.
